The risk of developing opportunistic infections such as meningitis, encephalitis and herpes increases due to an immunomodulation of NAT.[16] Up to now, there is no relevant systematic review and meta-analysis of clinical AEs of NAT. The gene discussed is BRD2; the disease is viral encephalitis.